Should I buy Pfizer (PFE) stock or is it too late?
⭐ The most reliable of them, either direction: BMO Capital — 73% of its targets hit on this sector (239 calls tested). It aims for $30 (+7.1 %), call made on July 14, 2026, maturing on July 14, 2027 (45 d ago).
Firm-by-firm track record on Pfizer
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Citigroup | 67 % | +9.7 % | 6 | $27 -4% |
| Morgan Stanley | 89 % | +9.2 % | 9 | $28 +0% |
| Jefferies | 65 % | +5.3 % | 23 | $39 +39% |
| Guggenheim | 80 % | +2.6 % | 5 | $31 +11% |
| B of A Securities | 50 % | +1.7 % | 6 | $26 -7% |
| BMO Capital | 43 % | +1.1 % | 14 | $30 +7% |
| Truist Securities | 14 % | -5.1 % | 7 | $32 +14% |
| Cantor Fitzgerald | 3 % | -14.9 % | 30 | $27 -4% |
✅ Reasons to believe
- Pays a dividend (7.2% yield), raised for 15 years — regular income on top of potential upside.
⚠️ Reasons to hesitate
- Even the most reliable firm on PFE, Barclays (100% hit rate, 2 scored calls), only targets $25 (call made on February 20, 2026, maturing on February 20, 2027) (-11%) in its most recent call. The stock may already have run past its target.
- The consensus is not unanimous: of 12 ratings, 8 are neutral.
- Limited upside: the median target is only +0% from the current price.
- High valuation (P/E ~37): strong growth is already "priced in", leaving little room for error.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
The analyst consensus on PFE
Median target $28 (+0%) · 12 ratings · Hold consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Pfizer now?
We won't decide for you. The facts: 33% of analysts rate it a buy, median target $28 (+0%), and Barclays (most reliable on PFE, 100%) targets $25. Weigh that against valuation (P/E ~37). This is not personalized advice.
Is it too late to invest in Pfizer?
The stated upside is small: the median target ($28) sits just +0% from the price ($28) (most reliable on PFE: Barclays, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Pfizer still worth investing in?
It depends on the gap between the price ($28) and its estimated value: analysts target $28 on median (+0%), with 33% buys (most reliable on PFE: Barclays, 100%). Cross-check with their real reliability on PFE and the cautions above. Information, not advice.
What's the main risk in buying PFE?
Even the most reliable firm on PFE, Barclays (100% hit rate, 2 scored calls), only targets $25 (call made on February 20, 2026, maturing on February 20, 2027) (-11%) in its most recent call. The stock may already have run past its target.
→ Go deeper: the full Pfizer profile (consensus, analyst reliability, price target, performance).